Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Immunization is increasingly recognized as a suitable therapeutic avenue for the treatment of neurological diseases such as Alzheimer's disease and other tauopathies. Tau is a key molecular player in these conditions and therefore represents an attractive target for passive immunization approaches. We performed such an approach in two independent tau transgenic mouse models of tauopathy, K369I tau transgenic K3 and P301L tau transgenic pR 5 mice. The antibodies we used were either specific for full‐length tau or tau phosphorylated at serine 404 (pS 404), a residue that forms part of the paired helical filament (PHF)‐1 phosphoepitope that characterizes tau neurofibrillary tangles in tauopathies. Although both pS 404 antibodies had a similar affinity, they differed in isotype, and only passive immunization with the IgG2a/κ pS 404‐specific antibody resulted in a lower tangle burden and reduced phosphorylation of tau at the PHF 1 epitope in K3 mice. In pR 5 mice, the same antibody led to a reduced phosphorylation of the pS 422 and PHF 1 epitopes of tau. In addition, histological sections of the hippocampal dentate gyrus of the immunized pR 5 mice displayed reduced pS 422 staining intensities. These results show that passive immunization targeting tau can modulate aspects of tau pathology in tau transgenic mouse models, in an antibody isotype‐specific manner. image We show that passive immunization targeting the pathological phosphorylation site pS404 on human tau with a monoclonal IgG2a/κ, but not a IgG1/κ antibody, reduced hyperphosphorylation of tau and tangle burden in two independent mouse models of tau pathology. This shows that both specificity and isotype of phospho‐tau (p‐tau)‐specific antibodies are important for therapeutically ameliorating tau pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 4×
“The widely used P301L tau transgenic pR5 mice develop NFT-like structures in the amygdala and hippocampus, with a relatively late but robust hyperphosphorylation of tau (Gotz et al. 2001a).”
BackgroundMethodInfluentialAnimal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676
Self-citationYanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506
Tau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495 · cited 4×
“The widely used P301L tau transgenic pR5 mice develop NFT-like structures in the amygdala and hippocampus, with a relatively late but robust hyperphosphorylation of tau (Gotz et al. 2001a).”
BackgroundMethodInfluentialSelf-citationThe importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475 · cited 2×
“Increased tau phosphorylation impairs the physiological functions of tau (Noble et al. 2013).”
BackgroundBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · cited 5×
“Previous studies support that tau-targeting passive immunotherapy is feasible and reduces tau pathology burden in mouse models (Boutajangout et al. 2011; Chai et al. 2011; Yanamandra et al. 2013; Castillo-Carranza et al. 2014).”
BackgroundInfluentialCastillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
Jeganathan, S., Hascher, A., Chinnathambi, S., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805300200 · Cited by 278
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · cited 1×
“In another study, active immunization targeting the S422 phosphoepitope was shown to reduce tau pathology in an independent mouse model (Troquier et al. 2012).”
BackgroundTauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein
Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178
Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · cited 8×
“This strategy was based on our previous findings that an active immunization using a PHF-1 containing phosphopeptide reduced the tau pathology in P301L tau transgenic pR5 mice (Bi et al. 2011).”
BackgroundMethodInfluentialSelf-citationTau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062402 · Cited by 144 · cited 3×
“Consistently, administering tau-specific antibodies as passive immunotherapy has been effective in independent mouse models of tau pathology (Boutajangout et al. 2011; Chai et al. 2011; Yanamandra et al. 2013; Castillo-Carranza et al. 2014; d’Abramo et al. 2013) and in an in vitro model (Gu et al.”
BackgroundPhosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
Grueninger, F., Bohrmann, B., Czech, C., Ballard, T. M., Frey, J. R., Weidensteiner, C., von Kienlin, M., & Ozmen, L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.004 · Cited by 117 · cited 1×
“For example, phosphorylation of epitope S422 has been linked to tangle formation (Grueninger et al. 2010).”
BackgroundRepeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66 · cited 2×
“Nevertheless, repeated immunization against phosphotau can also result in detrimental effects such as neuroinflammation (Rosenmann et al. 2006; Rozenstein-Tsalkovich et al. 2013).”
Background
Cited by
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Dendritic Tau in Alzheimer’s Disease
Ittner, A., & Ittner, L. M. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.003 · Cited by 278
Self-citationA walk through tau therapeutic strategies
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 290
Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer’s Disease Brain
DeVos, S. L., Corjuc, B. T., Oakley, D. H., Nobuhara, C. K., Bannon, R. N., Chase, A., Commins, C., Gonzalez, J. A., Dooley, P. M., Frosch, M. P., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00267 · Cited by 285
“This therapy has been shown both in vitro and in vivo to be successful at preventing both tau pathology formation and propagation (Boimel et al., 2010; Bi et al., 2011; Yanamandra et al., 2013; Castillo-Carranza et al., 2014; Ittner et al., 2015; Nicholls et al., 2017; Nobuhara et al., 2017).”
Background
Metadata
- Authors
- Ittner, A., Bertz, J., Suh, L. S., Stevens, C. H., Götz, J., & Ittner, L. M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2014-08
- Volume
- 132
- Issue
- 1
- Pages
- 135-145
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2021026087
- Cited by
- 82
- References
- 15
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.